scholarly journals Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study

Brain ◽  
2001 ◽  
Vol 124 (1) ◽  
pp. 145-153 ◽  
Author(s):  
J.-M. Leger ◽  
B. Chassande ◽  
L. Musset ◽  
V. Meininger ◽  
P. Bouche ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Controlled Study ◽  
Motor Neuropathy ◽  
Double Blind ◽  
Intravenous Immunoglobulin Therapy ◽  
Double Blind Placebo

Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study

Neurology ◽  
2000 ◽  
Vol 55 (9) ◽  
pp. 1256-1262 ◽  
Author(s):  
P. Federico ◽  
D.W. Zochodne ◽  
A.F. Hahn ◽  
W.F. Brown ◽  
T. E. Feasby
Keyword(s):  
Multifocal Motor Neuropathy ◽  
Controlled Study ◽  
Motor Neuropathy ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy

Neurology ◽  
1993 ◽  
Vol 43 (3, Part 1) ◽  
pp. 537-537 ◽  
Author(s):  
E. Nobile-Orazio ◽  
N. Meucci ◽  
S. Barbieri ◽  
M. Carpo ◽  
G. Scarlato
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
High Dose ◽  
Motor Neuropathy ◽  
Intravenous Immunoglobulin Therapy

scholarly journals How We Treat Autoimmune Small Fiber Polyneuropathy with Immunoglobulin Therapy

2018 ◽  
Vol 80 (5-6) ◽  
pp. 304-310 ◽  
Author(s):  
Jill R. Schofield ◽  
Kamal R. Chemali
Keyword(s):  
Intravenous Immunoglobulin ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Immunoglobulin Therapy ◽  
Multifocal Motor Neuropathy ◽  
Motor Neuropathy ◽  
Intravenous Immunoglobulin Therapy ◽  
Small Fiber ◽  
Immune Mediated ◽  
Inflammatory Demyelinating Polyneuropathy ◽  
Significant Efficacy

Intravenous immunoglobulin therapy is FDA approved for the immune-mediated peripheral nerve disorders Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Immunoglobulin therapy has been used increasingly with significant efficacy in the treatment of patients with disabling autoimmune forms of dysautonomia, which are most often small fiber (autonomic and/or sensory) polyneuropathies. It is recognized by most who treat these disorders, however, that patients with autonomic dysfunction treated with intravenous immunoglobulin therapy develop aseptic meningitis or severe lingering headache more frequently than other patient populations when this therapy is dosed in the traditional fashion. We discuss our combined 27 years of experience with the use of immunoglobulin and other immune modulatory therapy in patients with autoimmune small fiber polyneuropathy.

Sign in / Sign up

Export Citation Format

Share Document